Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

EXPLAINED: Mito org | Vintage Vibes

FGR accelerates USA expansion & defence sector exposure with strategic acquisition of MITO® Material Solutions

SYDNEY, June 4, 2026 /PRNewswire/ -- First Graphene Limited (ASX: FGR; "First Graphene" or "the Company") (FRA:M11) (OTCQB:FGPHF) is pleased to announce that it has entered a binding Sale Agreement ("Agreement") to acquire all product lines, manufacturing equipment and intellectual property of MITO® Material Solutions, Inc ("MITO"). Importantly, the...

AAP · Jun 4

Watch classy moment Daizen Maeda cleans facilities before training with ex-club

Celtic forward Daizen Maeda has gone back to his roots and recently trained with his former club Mito HollyHock.

The National (Scotland) · Jul 2, 2025

Arper’s Collection Just Launched at Salone del Mobile And Sets The Trends For The World We Want To Live In

At this year’s Salone del Mobile Arper will present their collection of responsible, expressive, and innovative products, with the planet’s care at the forefront

Livingetc · Apr 16, 2024

From analysis to the latest developments in health,
read the most diverse news in one place.

Alfa Romeo Baby Crossover Rendered Ahead Of 2024 Release

Could it be called MiTo?

Motor1 · May 1, 2023

Alfa Romeo's First EV Coming In 2024 Based On Jeep Avenger: Report

Alfa Romeo's first EV will reportedly arrive in June 2024 as the brand's smallest model since the MiTo subcompact hatchback was discontinued in 2018.

InsideEVs · Apr 12, 2023

Why Stealth BioTherapeutics Shares Are Surging Today?

Stealth BioTherapeutics Corp (NASDAQ:MITO) presented new SBT-272 preclinical data demonstrating functional improvement in upper motor neurons with TDP-43 pathology. TDP-43 pathology plays a significant role in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The data were presented at the Keystone Neurodegeneration Symposium. A Phase 1 study to evaluate the safety and tolerability…

Benzinga · Jun 8, 2022

Stealth Bio Posts Disappointing Elamipretide Data From Mid-Stage Geographic Atrophy Study

Stealth BioTherapeutics Corp (NASDAQ:MITO) has announced topline data from its Phase 2 ReCLAIM-2 trial evaluating elamipretide in geographic atrophy (GA) secondary to dry age-related macular degeneration. Although the trial did not meet its primary endpoints, a key secondary endpoint showed that elamipretide categorically improved visual function for patients with GA. The study did…

Benzinga · May 2, 2022

Read news from The Economist, FT, and more,
with one subscription

MITO: Stealth BioTherapeutics' Treatments Gain Momentum

By Brad Sorensen, CFA NASDAQ:MITO READ THE FULL MITO RESEARCH REPORT

Benzinga · Apr 1, 2022

Stealth Bio's SBT-272 Shows Encouraging Action In Huntington's Disease Animal Model

Stealth BioTherapeutics Corp (NASDAQ: MITO) announced the presentation of

Benzinga · Mar 31, 2022

Stealth BioTherapeutics Showcases New Nonclinical Data From Duchenne Muscular Dystrophy Program

Stealth BioTherapeutics Corp (NASDAQ: MITO) presented

Benzinga · Mar 17, 2022

Coverage From

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Department of Defence

Read news from The Economist, FT, and more,
with one subscription

Topics

Intellectual Property

394 stories

Macular Degeneration

62 stories

Amyotrophic lateral sclerosis

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.